- $193.22m
- $97.58m
- 53
- 31
- 86
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.67 | ||
| Price to Tang. Book | 1.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.42% | ||
| Return on Equity | -23.76% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.19 | 30.98 | 15.62 | 9.16 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Directors
- Ronald Renaud NEC (52)
- Mark Manfredi PRE (50)
- Douglas Carlson COO (42)
- Alfredo Castro SVP
- Michelle Zhang SVP
- Jeffrey Ecsedy CSO (51)
- Karen McGovern VPR
- Sergio Santillana OTH (58)
- Maude Tessier OTH (43)
- David Bonita IND (45)
- Iain Dukes IND (62)
- Jean-Francois Formela IND (64)
- Otello Stampacchia IND (51)
- Richard Wooster IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- March 2nd, 2016
- Public Since
- March 26th, 2021
- No. of Shareholders
- 42
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 11,181,676
- Address
- 12526 High Bluff Drive, Suite 345, SAN DIEGO, 02210
- Web
- https://inmagenebio.com/
- Phone
- +1 8572738343
- Auditors
- Ernst & Young LLP
Similar to IMA
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 12:16 UTC, shares in ImageneBio are trading at $17.28. This share price information is delayed by 15 minutes.
Shares in ImageneBio last closed at $17.28 and the price had moved by -14.29% over the past 365 days. In terms of relative price strength the ImageneBio share price has underperformed the S&P500 Index by -26.53% over the past year.
The overall consensus recommendation for ImageneBio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreImageneBio does not currently pay a dividend.
ImageneBio does not currently pay a dividend.
ImageneBio does not currently pay a dividend.
To buy shares in ImageneBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $17.28, shares in ImageneBio had a market capitalisation of $193.22m.
Here are the trading details for ImageneBio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMA
Based on an overall assessment of its quality, value and momentum ImageneBio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ImageneBio is $3,312.13. That is 19067.43% above the last closing price of $17.28.
Analysts covering ImageneBio currently have a consensus Earnings Per Share (EPS) forecast of -$83.52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImageneBio. Over the past six months, its share price has underperformed the S&P500 Index by -6.5%.
As of the last closing price of $17.28, shares in ImageneBio were trading +0.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ImageneBio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ImageneBio's management team is headed by:
- Ronald Renaud - NEC
- Mark Manfredi - PRE
- Douglas Carlson - COO
- Alfredo Castro - SVP
- Michelle Zhang - SVP
- Jeffrey Ecsedy - CSO
- Karen McGovern - VPR
- Sergio Santillana - OTH
- Maude Tessier - OTH
- David Bonita - IND
- Iain Dukes - IND
- Jean-Francois Formela - IND
- Otello Stampacchia - IND
- Richard Wooster - IND